EpiBiologics

Executive Summary

EpiBiologics is a San Diego-based biotechnology company pioneering targeted protein degradation of extracellular and membrane proteins using its proprietary EpiTAC platform. Founded in 2020, the company addresses a significant unmet need in the proteome by leveraging bispecific antibody technology to selectively remove disease-causing proteins that are inaccessible to traditional intracellular degradation approaches. This innovative strategy positions EpiBiologics to tackle a wide range of therapeutic areas, including oncology, immunology, and neurology, where extracellular protein dysregulation plays a key role. The platform's versatility and potential for high specificity could offer advantages over existing degradation modalities and conventional antibody therapies. As a privately held, early-stage company, EpiBiologics is likely focused on advancing its lead programs toward preclinical proof-of-concept and identifying strategic partnerships to accelerate development. The biotech's ability to differentiate its technology in a competitive landscape will be critical for attracting investment and collaborations. While specific pipeline details are undisclosed, the company's unique focus on the extracellular proteome and its bispecific antibody approach represent a promising frontier in targeted protein degradation. Near-term catalysts include potential funding rounds, research collaborations, or preclinical data presentations that could validate the platform's utility and drive value creation.

Upcoming Catalysts (preview)

• H2 2026Series A or B funding round70% success
• 2027Preclinical proof-of-concept data for lead program50% success
• TBDStrategic partnership with a larger pharma company40% success